Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 40Specimen Handling 36Nivolumab 29enzalutamide 27pembrolizumab 22Gemcitabine 22Docetaxel 21Prednisone 19apalutamide 18Biopsy 17Abiraterone Acetate 17Androgen Antagonists 15cabozantinib 14abiraterone 12Radiotherapy 12Cisplatin 12enfortumab vedotin 11darolutamide 11Ipilimumab 11Pluvicto 10erdafitinib 9atezolizumab 9X-Rays 9Radiation 9Mitomycin 9olaparib 8belzutifan 8Standard of Care 8Radiosurgery 82-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Receptors, Vascular Endothelial Growth Factor × Genitourinary × 30 days × Clear all
NCT04777994 2026-06-04

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Calico Life Sciences LLC

Phase 1 Recruiting
248 enrolled
GenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡